Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(166 produits)
- Bcr-Abl(117 produits)
- EGFR(581 produits)
- FAK(72 produits)
- FLT(86 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(180 produits)
- JAK(243 produits)
- PDGFR(129 produits)
- RAAS(89 produits)
- Src(82 produits)
- Syk(37 produits)
- Thrombine(57 produits)
- VDA(2 produits)
- VEGFR(242 produits)
Affichez 6 plus de sous-catégories
2379 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
KIT/PDGFRA-IN-1
KIT/PDGFRA-IN-1 (compound 19) is an inhibitor targeting the stem cell growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA). Its IC50 values are 2.3 µM for KIT-wt, 12 µM for KIT-D816H, 492 µM for KIT-T670I, 0.8 µM for PDGFRA-wt, 99.9 µM for PDGFRA-D842V, 42.3 µM for PDGFRA-T674I, and 4.3 µM for PDGFRA-G680R. The GR50 values for GIST-T1, T1-a-D842V, and GIST-48B cell lines (gastrointestinal stromal tumor cell lines with PDGFR and KIT mutations) are 12 nM, 8900 nM, and ≥10,000 nM, respectively.Formule :C26H18F3N5O2Couleur et forme :SolidMasse moléculaire :489.449SJ1008030 formic
SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with anFormule :C43H45N13O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :919.96hCA/VEGFR-2-IN-2
Compound 8g (hCA/VEGFR-2-IN-2) is an indolinonylbenzenesulfonamide identified as a potential dual inhibitor targeting cancer-associated isozymes hCA IX/XII andFormule :C23H26N6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :498.55(R)-3-Hydroxy Midostaurin
CAS :(R)-3-Hydroxy Midostaurin: potent kinase inhibitor, major midostaurin metabolite via CYP3A4, potential AML treatment.Formule :C35H30N4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :586.648AZ12672857
CAS :AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM.
Formule :C26H30N8O2Degré de pureté :98.99%Couleur et forme :SolidMasse moléculaire :486.57EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formule :C49H32N12O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :884.99Hck-IN-2
Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.Formule :C36H35FN6O10Couleur et forme :SolidMasse moléculaire :730.696PROTAC FGFR1 degrader-1
PROTAC FGFR1 degrader-1 (compound S2H) is a targeted degrader of FGFR1, demonstrating an IC50 of 26.81 nM and a DC50 of 39.78 nM in KG1a cells. This compound is composed of a CRBN-type E3 ligase ligand (blue part) Pomalidomide, a target protein ligand (red part) FGFR1ligand-1, and a PROTAC linker (black part) 9-Bromononanoic acid, together forming the conjugate E3LigaseLigand-linker Conjugate 164.Formule :C46H54N8O8Couleur et forme :SolidMasse moléculaire :846.97JH-XI-10-02
CAS :JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formule :C53H69N5O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :920.161ABP-102
ABP-102 (CT P72) is a bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for targeting HER2 overexpressing tumors.Couleur et forme :Odour LiquidPROTAC EGFR degrader 7
Compound 13b, a potent EGFR degrader, inhibits and induces apoptosis in NSCLC cells with a DC50 of 13.2 nM.Formule :C46H48N10O6Couleur et forme :SolidMasse moléculaire :836.94VSLRGDTRG
CAS :VSLRGDTRG is a synthetic peptide derived from the RGD motif in cadherin17 (CDH17) that binds to the α2β1 integrin, activating its signaling pathways. By promoting high-affinity conformational changes in β1 integrins through the RGD motif, VSLRGDTRG enhances cell adhesion and the phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. This peptide is useful for research on cancers expressing CDH17, such as colorectal and pancreatic cancer.Formule :C38H69N15O14Couleur et forme :SolidMasse moléculaire :960.047INCB-000928
CAS :Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.
Formule :C30H38N4O3Degré de pureté :98.93%Couleur et forme :SolidMasse moléculaire :502.65SOS1/EGFR-IN-2
SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.Formule :C25H29F3N4O3Couleur et forme :SolidMasse moléculaire :490.52PROTAC EGFR degrader 4
CAS :PROTAC EGFR degrader 4 targets mutant EGFR, degrades del19 and L858R/T790M (DC50: 0.51, 126 nM), and inhibits HCC827, H1975 cell growth (IC50: 0.83, 203.1 nM).Formule :C55H70N12O4SCouleur et forme :SolidMasse moléculaire :995.29BV02
CAS :BV02 blocks 14-3-3 interactions, useful in chronic myeloid leukemia research, targets T315I mutant and wild-type Bcr-Abl cells.Formule :C20H15N3O5Degré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :377.35Ref: TM-T60081
2mg34,00€5mg52,00€10mg80,00€25mg161,00€50mg245,00€100mg363,00€200mg515,00€1mL*10mM (DMSO)58,00€SC209
CAS :SC209, a STRO-002 metabolite from patent WO2021247798, synthesizes anti-EGFR ADCs.Formule :C27H44N4O4Couleur et forme :SolidMasse moléculaire :488.66SNIPER(ABL)-015
SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5Formule :C58H70F3N9O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1094.23Sorafenib-d4
CAS :Sorafenib D4 is deuterium-labeled Sorafenib, a multi-kinase inhibitor (Raf-1, B-Raf, VEGFR-3) with IC50s: 6, 20, 22 nM.Formule :C21H16ClF3N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :468.85HIF-1 inhibitor-4
CAS :HIF-1 inhibitor-4 (HIF-1 inhibitor-4) is a HIF-1 inhibitor with IC50 of 560 nM.Formule :C18H19IN2O2Degré de pureté :99.26%Couleur et forme :SolidMasse moléculaire :422.26Multi-kinase-IN-5
Multi-kinase-IN-5 (compound 15c) is a multi-kinase inhibitory agent that shows significant inhibition against a range of protein kinases including RET, KIT,Formule :C19H15N5O2SCouleur et forme :SolidMasse moléculaire :377.42SJ988497
CAS :SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.Formule :C36H36N10O5Couleur et forme :SolidMasse moléculaire :688.74FLT3-IN-22
FLT3-IN-22 (compound 22f) is a potent inhibitor of FLT3, demonstrating IC50 values of 0.941 nM for FLT3 and 0.199 nM for the FLT3/D835Y mutant.Formule :C24H22N6O2Couleur et forme :SolidMasse moléculaire :426.47IMC-D11
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.Couleur et forme :Odour LiquidSNIPER(ABL)-047
SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels,Formule :C67H82F3N11O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1274.5Src Inhibitor 4
Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.Formule :C33H34N4O3Couleur et forme :SolidMasse moléculaire :534.648DB1113
CAS :DB1113 is a bifunctional kinase degrader, targeting ABL1, ABL2, CDK4, MAPKs, and more for disease research.Formule :C59H68F3N13O6SCouleur et forme :SolidMasse moléculaire :1144.31CPD-1224
CAS :CPD-1224, an oral ALK inhibitor derivative, binds cereblon, targets EML4-ALK fusions, and degrades ALK plus L1196M/G1202R mutants.Formule :C43H47ClN8O7SCouleur et forme :SolidMasse moléculaire :855.4IBI-334
IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.Couleur et forme :Odour LiquidPF15 TFA
PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.Formule :C46H50F3N13O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :969.97PST3.1a
CAS :PST3.1a is a selective inhibitor of Mannoside acetyl glucosaminyltransferase 5 (MGAT5), used for studying glioblastoma multiforme (GBM). PST3.1a inhibits TGF-βR and FAK signalling associated with doublecortin (DCX), increases OLIG2 expression, and suppresses the invasion and proliferation of GBM initiator cells (GICs).Formule :C32H33O6PCouleur et forme :SolidMasse moléculaire :544.57EGFR-IN-78
EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.Formule :C23H32BrN7O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :550.51VEGFR-2-IN-64
VEGFR-2-IN-64 (Compound 28) is an inhibitor of VEGFR2 with an IC50 of 27.8 nM. It suppresses the proliferation of cancer cells A549, T-47D, and Caco-2, exhibits anti-migration and anti-colony formation activities in T-47D cells, and induces apoptosis in T-47D cells.Formule :C72H123N9O6Couleur et forme :SolidMasse moléculaire :1210.8BTK-IN-5
CAS :BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,Formule :C23H32N4O5Couleur et forme :SolidMasse moléculaire :444.532Coumermycin A1
CAS :Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria.Formule :C55H59N5O20Couleur et forme :SolidMasse moléculaire :1110.092AKN-028
CAS :AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.
Formule :C17H14N6Degré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :302.33K882
K882 (Compound 4e) is an Src inhibitor with a KD of 0.315 μM. It induces apoptosis and inhibits XIAP and Survivin. Additionally, K882 blocks the activation of the PI3K/Akt/mTOR, Jak1/Stat3, and Ras/MAPK signaling pathways. K882 exhibits antitumor activity against non-small cell lung cancer.Formule :C18H16N2O2Couleur et forme :SolidMasse moléculaire :292.33TYK2 activator-1
TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.Formule :C23H21FN4O2Couleur et forme :SolidMasse moléculaire :404.16485FLT3/VEGFR2-IN-1
FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.Formule :C29H35N7O5Couleur et forme :SolidMasse moléculaire :561.63SI-2
CAS :SI-2, a SRC-3 inhibitor, triggers breast cancer cell death (IC50: 3-20 nM), sparing normal cells.Formule :C15H15N5Degré de pureté :98.4%Couleur et forme :SolidMasse moléculaire :265.31Ref: TM-T28773
1mg358,00€5mg873,00€10mg1.161,00€25mg1.755,00€50mg2.358,00€100mg3.177,00€1mL*10mM (DMSO)800,00€BW710
BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.Formule :C28H29FN6O2SCouleur et forme :SolidMasse moléculaire :532.637-Hydroxyneolamellarin A
CAS :7-Hydroxyneolamellarin A, from Dendrilla nigra, inhibits HIF-1α and VEGF in cancer research.Formule :C24H19NO5Couleur et forme :SolidMasse moléculaire :401.41Tyrosinase-IN-16
CAS :Tyrosinase-IN-16 inhibited tyrosinase.Formule :C8H6BrN3SDegré de pureté :99.94%Couleur et forme :SolidMasse moléculaire :256.12HER2/neu (654-662) GP2
CAS :Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.Formule :C42H77N9O11Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :884.11FAK-IN-24
CAS :FAK-IN-24 (Compound 9f) is a potent FAK inhibitor with an IC50 of 0.815 nM. It induces DNA damage and apoptosis, and exhibits activity against glioblastoma. FAK-IN-24 effectively inhibits proliferation of glioblastoma cell lines U87-MG (IC50= 15 nM) and U251 (IC50= 20 nM), and suppresses tumor growth in U87-MG xenograft models.Formule :C39H45Cl2F3N8O3Couleur et forme :SolidMasse moléculaire :801.728JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Formule :C28H38N6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :570.7Lewis y tetrasaccharide
CAS :Lewis Y tetrasaccharide, a derivative of Lewis X, is an antigen linked to ovarian cancer metastasis and bad prognosis.Formule :C26H45NO19Couleur et forme :SolidMasse moléculaire :675.63AXL/Angiokinase-IN-1
AXL/Angiokinase-IN-1 (compound 11b) is an inhibitor of AXL/triple angiokinase, with an IC50 of 3.75 nM for AXL expression. This compound suppresses epithelial-mesenchymal transition (EMT) in Bxpc-3 cells and prevents metastasis in lung cancer cells. Additionally, AXL/Angiokinase-IN-1 impairs the functions of vascular and fibroblast cells and induces apoptosis in both cancer and fibroblast cells. It is characterized by low toxicity and favorable metabolic stability.Formule :C31H34ClN5O2Couleur et forme :SolidMasse moléculaire :544.09Tephrosin
CAS :Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.Formule :C23H22O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :410.42EGFR-IN-43
EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.Formule :C50H55ClFN5O5Couleur et forme :SolidMasse moléculaire :860.45
